This page was last updated on 05/18/2020. Please check back frequently for updates.
CancerLinQ is monitoring COVID diagnoses among active cancer patients in our database of 1.5 million total cancer patients from participating organizations. COVID disease is being detected by searching for positive tests for the SARS-CoV-2 virus and/or diagnosis of COVID disease and/or diagnosis of viral pneumonia not attributed to known agents. These cases have been characterized by age, gender, race, ethnicity, and cancer diagnosis. In addition, we have provided similar distributions for all active cancer patients from the sites that are reporting COVID disease (“Baseline Cases”) for purposes of comparing the COVID infected cancer population with the non-infected patient populations at the same sites.
Visit the CancerLinQ website to access this series of reports.
To complement the clinical data gathered by CancerLinQ, ASCO’s PracticeNET program has compiled data on practice activity from its benchmarking collaborative. Starting in March 2020, a group of 16 practices have shared weekly data in order to analyze the impact of COVID-19 on practice operations.
Observations from this data include:
- Starting the week of March 16, 2020, there was:
- A 40% decrease in total visit activity, including new patient visits, established patient visits, and hospital visits.
- A fall in new patient and consult activity, primarily for patients with blood cancers and benign hematology disorders.
- Growth in telehealth (audio/visual), telephone-only visits, e-visits, and virtual check-ins.
- Since March 15, among available telemedicine services, 37% were telehealth visits (audio/visual), 46% were telephone-only visits, and 15% were virtual check-ins. Telehealth visits have increased in recent weeks.
- Overall physician work relative value units (a measure which impacts various aspects of staffing and reimbursement) has decreased approximately 30%.
- While chemotherapy infusion visits have not significantly changed, there has been a sustained decrease in non-chemotherapy drug infusions.
- In the month of April, an increase in the use of hematopoietic colony stimulating factors (e.g. white blood cell colony stimulating factors) has occurred.